Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Enveric Biosciences (ENVB) reported additional preclinical findings supporting that its primary candidate EB-003 is non-hallucinogenic. The update is incremental and primarily reinforces the drug’s safety/side-effect profile rather than introducing new clinical efficacy data, likely limiting near-term impact beyond biotech-specific sentiment.

Analysis

Enveric Biosciences (ENVB) reported additional preclinical findings supporting that its primary candidate EB-003 is non-hallucinogenic. The update is incremental and primarily reinforces the drug’s safety/side-effect profile rather than introducing new clinical efficacy data, likely limiting near-term impact beyond biotech-specific sentiment.